

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 3241850 T3**

-
- (51) Int.Cl.: *C 07 K 19/00 (2006.01)* *A 61 K 38/26 (2006.01)* *A 61 P 1/00 (2006.01)*
A 61 P 1/12 (2006.01) *A 61 P 3/08 (2006.01)* *A 61 P 3/10 (2006.01)*
C 07 K 14/605 (2006.01) *C 07 K 16/00 (2006.01)*
- (45) Oversættelsen bekendtgjort den: **2019-11-04**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-09-04**
- (86) Europæisk ansøgning nr.: **15875748.4**
- (86) Europæisk indleveringsdag: **2015-12-31**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-11-08**
- (86) International ansøgning nr.: **KR2015014542**
- (87) Internationalt publikationsnr.: **WO2016108654**
- (30) Prioritet: **2014-12-31 KR 20140195793**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Genexine, Inc., 4th Fl., Bldg. B, Korea Bio Park , Daewangpangyo-ro 700 , Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Sydkorea**
- (72) Opfinder: **SUNG, Young Chul, 101-404, 67 Seobinggo-ro, Yongsan-gu, Seoul 04385, Sydkorea**
YANG, Se Hwan, 501ho, 18 Sadang-ro 2cha-gil, Dongjak-gu, Seoul 07030, Sydkorea
BYUN, Mi Sun, Na-102, 93 Bucheon-ro 366beon-gil, Wonmi-gu, Bucheon-si, Gyeonggi-do 14481, Sydkorea
YANG, Sang In, 201ho, 29 Hyeonchung-ro 18-gil, Nam-gu, Daegu 42450, Sydkorea
SHIN, Eun Ju, 506-902, 16 Simgok-ro, Suji-gu, Yongin-si, Gyeonggi-do 16862, Sydkorea
- (74) Fuldmægtig i Danmark: **Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, F-92665 Asnières-sur-Seine cedex, Frankrig**
- (54) Benævnelse: **FUSIONSPOLYPEPTID FOR GLP OG EN HYBRID IMMUNOGLOBULIN FC OG ANVENDELSEN DERAFT**
- (56) Fremdragne publikationer:
KR-A- 20140 037 961
US-A1- 2008 300 188
US-A1- 2012 189 627
US-A1- 2013 217 864
US-A1- 2014 377 290
SE JIN IM ET AL: "Natural Form of Noncytolytic Flexible Human Fc as a Long-Acting Carrier of Agonistic Ligand, Erythropoietin", PLOS ONE, vol. 6, no. 9, 16 September 2011 (2011-09-16), page e24574, XP055468250, DOI: 10.1371/journal.pone.0024574
JUNG-HWAN LEE ET AL: "Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells", PROTEIN EXPRESSION AND PURIFICATION., vol. 87, no. 1, 1 January 2013

Fortsættes ...

(2013-01-01), pages 17-26, XP55333326, SAN DIEGO, CA. ISSN: 1046-5928, DOI: 10.1016/j.pep.2012.09.001
SE HWAN YANG ET AL: "A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia", ARCHIVES OF PHARMACAL RESEARCH, PHARMACEUTICAL SOCIETY OF KOREA, HEIDELBERG, vol. 35, no. 5, 29 May 2012 (2012-05-29), pages 757-759, XP035063549, ISSN: 1976-3786, DOI: 10.1007/S12272-012-0500-5
KIM ET AL.: 'Fc Fusion to Glucagon-like Peptide-1 Inhibits Degradation by Human DPP-IV, increasing its Half-Life in Serum and inducing a Potent Activity for human GLP-1 Receptor Activation' BMB REPORTS vol. 42, no. 4, 01 January 2009, pages 212 - 216, XP055460879 DOI: 10.5483/BMBREP.2009.42.4.212
GLAESNER ET AL.: 'Engineering and Characterization of the Long-Acting Glucagon-like Peptide-1 Analogue LY2189265, an Fc fusion Protein' DIABETES/METABOLISM RESEARCH AND REVIEWS, [Online] vol. 26, no. 4, 01 May 2010, pages 287 - 296, XP055181624 DOI: 10.1002/DMRR.1080

DESCRIPTION

[Technical Field]

[0001] The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. Additionally, a polynucleotide encoding the fusion polypeptide, an expression vector containing the polynucleotide, and a host cell containing the expression vector are also included in the scope of the present invention.

[Background Art]

[0002] Diabetes is a metabolic disease, which causes a problem in insulin secretion or insulin function due to genetic or environmental reasons and thus the glucose in the blood cannot be utilized as an energy source for cells, thereby showing the symptoms of hyperglycemia having high blood glucose levels. Diabetes can cause complications and is one of the most serious chronic diseases in modern society.

[0003] Diabetes can be largely classified into type 1 diabetes and type 2 diabetes. Type 1 diabetes accounts for less than 10% of the total diabetic patients and mostly occurs in children. Reportedly, type 1 diabetes occurs when the pancreatic β cells fail to produce or secrete insulin by their destruction due to auto-immune diseases, etc., and thus type 1 diabetic patients require lifetime insulin injections. In contrast, type 2 diabetes accounts for 90% or more of the total diabetic patients and mostly occurs in adults, and in particular, more frequently in overweight and obese adults. Reportedly, type 2 diabetes is caused by defective insulin secretion or insulin resistance in the pancreas.

[0004] For the treatment of diabetes, people usually start with physical exercise and diet therapy. However, when these efforts fail to control the blood glucose levels, a single or combined diabetic agent may be administered. According to the American Diabetes Association (ADA) guidelines, the first-selection drug is metformin, the second- and third-selection drugs include sulfonylurea-based, glinide-based, thiazolidinedione-based, DPP-4 inhibitors, etc., and injections, such as a glucagon like peptide-1 (GLP-1) agonist, or insulin injections are followed thereafter.

[0005] The conventional oral therapeutic agents currently used in clinical treatment have the advantage of capable of continuously maintaining normal blood glucose levels, however, the

long-term administration of these agents not only causes various adverse effects such as causing hypoglycemia, diarrhea, body weight gain, cardiovascular problems, hepatotoxicity, etc., but also causes destruction of the pancreatic β cells, thereby ultimately requiring an insulin injection. Additionally, the insulin injection, as the final treatment, must be administered subcutaneously two to three times daily thus causing inconveniences, and the insulin injection may possibly induce hypoglycemia, which is one of the most serious adverse effects.

[0006] While making efforts to remedy these problems, GLP-1 has been on the spotlight recently as the next generation diabetes treatment. GLP-1 and analogs and derivatives thereof have shown good potentials as therapeutic agents for treating type 2 diabetes in clinical trials. They can induce numerous biological effects, such as stimulating insulin secretion, inhibition of glucagon secretion, inhibition of gastric emptying, inhibition of gastric- or intestinal motility, induction of reducing body weight, etc. Additionally, they can protect the pancreas during a long-term administration, are free of hypoglycemia, and maintain appropriate blood glucose levels for a long period of time.

[0007] However, GLP-1 is degraded by DPP-4 *in-vivo* and becomes inactive thereby having a very short half-life *in-vivo*, which makes it difficult to be developed as a therapeutic agent. Accordingly, various approach methods have been conducted in order to prolong the half-life of GLP-1 or reduce the peptide removal rate from the body while maintaining its biological activities. That is, various GLP-1 analogs have been actively developed, and an approach method to fuse GLP-1 to an immunoglobulin Fc region has been attempted (U.S. Pat. No. 7,452,966 B2, etc.).

[0008] Nevertheless, the application of the technology to fuse immunoglobulin Fc has not progressed sufficiently for its commercialization, from the aspect of limitations in half-life, antibody-dependent cell cytotoxicity (ADCC)-inducing capacity, stability for DPP-4 enzyme, etc.

[0009] Meanwhile, inflammatory bowel disease (IBD) is thought to occur due to genetic and immunological factors, however, it is an incurable disease in which the causes and treatments still remain to be elucidated. It is a chronic disease caused by the inflammation on the inner wall of the digestive tract, and inflammatory bowel diseases are largely classified into ulcerative colitis and Crohn's disease.

[0010] Ulcerative colitis (UC) is a chronic inflammatory disease which occurs on the mucous membrane of the large intestine of the digestive tract, and the inflammation begins from the rectum and is continuously connected to the large intestine. Patients with ulcerative colitis commonly complain of diarrhea, bloody stool, abdominal pain, etc., and symptoms such as anorexia, weight loss, fatigue, etc., are often accompanied as well. In most cases, ulcerative colitis is an intermittent disease repeatedly featuring the periods of exacerbated symptoms and those of ameliorated symptoms, and sometimes there are also long periods that are symptom-free.

[0011] In Crohn's disease (CD), unlike ulcerative colitis, inflammation invades the entire layers

of the intestine and the distribution of lesions is not continuous but is rather scattered around in many cases. The frequently occurring symptoms of Crohn's disease include diarrhea, abdominal pain, anorexia, etc., but the kinds and degrees of the symptoms vary greatly depending on the patients. In fact, the patients with Crohn's disease appear to experience more severe pain compared to those with ulcerative colitis, and the long-term progress and responses to treatments of the patients with Crohn's disease are much worse, thus often making them undergo surgery.

[0012] Although the effective treatment leading to a complete cure of inflammatory bowel disease is still not known because the causes of the inflammatory bowel disease have not been identified yet, studies on the factors affecting the progress of the inflammatory bowel disease have been considerably advanced, and various drugs for reducing inflammation have been developed and are currently in use. The therapeutic agents for inflammatory bowel disease widely used at present are applied sequentially in the order of anti-inflammatory agents (5-aminosalicylic acid; 5-ASA), steroidal agents, immunosuppressive agents such as 6-mercaptopyrine (6-MP), and biological agents such as TNF α inhibitors (anti-TNF α antibody, Infliximab), according to the severity of symptoms. However, these agents currently in use have shown various adverse effects, and accordingly, there is an urgent need for the development of 1) a biological agent having the efficacy to compensate or replace that of the existing drugs, or 2) a biological agent employing a mechanism different from that of the existing drugs.

[0013] In an effort to compensate these problems, GLP-2 has been on the spotlight recently as a therapeutic agent for inflammatory bowel disease. GLP-2, which is secreted from the L cells in the intestine, induces the production of IGF-1, nitric oxide (NO), vasoactive intestinal peptide (VIP), etc., through the signaling of GLP-2 receptors expressed in the intestinal cells. The thus-produced IGF-1 induces the growth of the intestinal cells through the signaling of PI-3K and AKT, and NO helps to improve the blood circulation in the intestine. Additionally, since GLP-2 is known to have the anti-inflammatory effect by inducing VIP production, it is also being experimentally confirmed in various research groups that GLP-2 is effective for the treatment of short bowel syndrome as well as for inflammatory bowel disease.

[0014] In fact, Gattex® (teduglutide), a GLP-2 analog, was developed by NPS pharmaceuticals, Inc. (USA) at the end of 2012, approved as an orphan drug for the treatment of short bowel syndrome (SBS), and after expanding indications, it is currently in clinical phase 2 studies among patients with inflammatory bowel disease.

[0015] However, although Gattex® has a significantly increased half-life compared to that of native GLP-2, it should be also injected once daily, thus still not satisfying unmet needs from the aspect of patient convenience. Furthermore, when the drug is to be applied to inflammatory bowel disease, which is an autoimmune disease requiring lifetime treatment, it should be developed in the form of a long-acting therapeutic agent that can be administered from at least once a week to once a month. That is, since GLP-2 is a peptide hormone, it has a significantly decreased duration compared to that of protein drugs, and thus there is a need for

a method of improving the long-term duration of GLP-2.

[0016] On the other hand, since cancer cells are characterized by having rapid growth and division, most anticancer agents are designed to kill rapidly growing cells. However, some normal cells also grow rapidly like cancer cells and thus these normal cells are also damaged by anticancer chemotherapy. The rapidly growing and dividing cells among normal cells, i.e., blood cells formed in bone marrow, epithelial cells in the gastrointestinal tract containing oral cavity, hair cells, and germ cells, which produce sperms and ova, are affected more seriously. In particular, anticancer agents frequently cause mucositis in the gastrointestinal tract which may cause diarrhea, and in the case of serious diarrhea, ringer's solution and nutrients should be supplied via intravenous injection to prevent dehydration. In such a case, the preset anticancer chemotherapy schedule may have to be changed thus considerably affecting on cancer treatment. Accordingly, it is considered essential to prevent endoenteritis or diarrhea caused by anticancer chemotherapy in advance because it can reduce the pain of patients while maximizing anticancer effect. In the case of GLP-2, it can induce the proliferation of crypt cells, which form the villi of the small intestine, thereby capable of rapidly recovering from adverse effects due to anticancer chemotherapy, and the development of a GLP-2 analog with a long-term duration can prevent endoenteritis or diarrhea caused by anticancer chemotherapy in advance, by means of one injection for each cycle.

[0017] Under these circumstances, the present inventors, in order to develop a long-acting therapeutic agent by increasing the *in-vivo* half-lives of short-length peptides containing GLP, such as GLP-1 and GLP-2, employed the immunoglobulin hybrid Fc technology disclosed in International Publication No. WO 2008-147143, which was filed previously by the present inventors, selected the immunoglobulin Fc optimized to be specific to glucagon-like peptide (GLP), and prepared a fusion polypeptide with excellent resistance to DPP-4 enzyme while having an increased half-life, thereby completing the present invention.

[Disclosure]

[Technical Problem]

[0018] An object of the present invention is to provide a fusion polypeptide including (a) glucagon-like peptide (GLP) or an analog thereof; and (b) an immunoglobulin Fc polypeptide containing a limited number of IgD hinge region.

[0019] Another object of the present invention is to provide a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide as an active ingredient.

[0020] Still another object of the present invention is to provide a polynucleotide encoding the fusion polypeptide, an expression vector including the polynucleotide, and a host cell including the expression vector.

[Technical Solution]

[0021] In order to achieve the above objects, in an aspect, the present invention provides a fusion polypeptide including (a) GLP or an analog thereof; and (b) an immunoglobulin Fc polypeptide containing a limited number of IgD hinge regions.

[0022] Specifically, the fusion polypeptide may include (a) glucagon-like peptide (GLP) or an analog thereof, and (b) an immunoglobulin Fc polypeptide, in which the immunoglobulin Fc polypeptide includes (i) an isolated IgD hinge region consisting of an amino acid sequence of 35 to 49 consecutive amino acid residues from the C-terminus of SEQ ID NO: 25; and (ii) a CH2 domain and a CH3 domain consisting of an amino acid sequence of SEQ ID NO: 29.

[0023] Preferably, the C-terminus of the GLP or an analog thereof may be conjugated to the N-terminus of the immunoglobulin Fc polypeptide, and within the immunoglobulin Fc polypeptide, the C-terminus of the IgD hinge region may be conjugated to the N-terminus of the CH2 domain and the CH3 domain. Accordingly, the GLP or an analog thereof; the IgD hinge region; and the CH2 domain and the CH3 domain may be sequentially conjugated from the N-terminus to the direction of the C-terminus. As used herein, the term "fusion polypeptide" refers to a form in which a biologically active molecule, such as GLP, and the immunoglobulin Fc polypeptide are fused together, and may be used interchangeably with terms such as "Fc fusion polypeptide" and "fusion protein".

[0024] In the present invention, the glucagon-like peptide (GLP) is a concept encompassing both GLP-1 and GLP-2.

[0025] Although GLP-1 and GLP-2 peptides differ from each other in terms of *in-vivo* action mechanism and functions, they, being peptides produced from a single mRNA precursor of the proglucagon gene, have a high amino acid sequence homology, have the same cleavage site for DPP-4 enzyme, and are hormones having similar molecular characteristics. Therefore, when the glucagon-like peptide (GLP) containing GLP-1 or GLP-2 is conjugated to the immunoglobulin Fc polypeptide, a similar form may be applied. Specifically, when the GLP is conjugated to the hybrid Fc (hyFc) polypeptide developed by the present inventors, a similar form of hyFc may be applied thereto.

[0026] As used herein, the term "GLP-1 (glucagon-like peptide-1)" is a type of incretins, which are hormones secreted in the digestive tract. In fact, GLP-1 is a protein secreted from intestinal L-cells in a diet-dependent manner known to play the role of increasing pancreatic insulin secretion and the role of inhibiting the increase of blood glucose levels after a meal by inhibiting the secretion of glucagon. As such, the therapeutic use of GLP-1 for treating diabetes

has already been widely known, and there is also a report that GLP-1 is involved in the physiological control of appetite thus having an effect of reducing body weight.

[0027] On the other hand, the native GLP-1 is processed *in-vivo* so that the initial six amino acids can be cleaved from the molecule. According to the customary practice in the art to which the present invention pertains, the N-terminus of GLP-1 is designated as No. 7 while the C-terminus of GLP-1 is designated as No. 37. According to the process, GLP-1 may be processed from the GLP-1 (1-37), a form without the function of insulin secretion, into a form of the GLP-1 (7-37) (the amino acid sequence of SEQ ID NO: 1 and the nucleic acid sequence of SEQ ID NO: 33) to be an active form, and may be further modified *in-vivo* so that the glycine residue at the C-terminus can be removed and replaced with an amide group, thereby becoming GLP-1 (7-36) amide (the amino acid sequence of SEQ ID NO: 3 and the nucleic acid sequence of SEQ ID NO: 35). Accordingly, GLP-1(7-37) OH and GLP-1(7-36) amide correspond to two native types of GLP-1.

[0028] However, native GLP-1 has many limitations to be developed as a drug because, for example, it is very rapidly cleaved *in-vivo* by DPP-4 enzyme and becomes inactive, and thus there have been many attempts to increase its *in-vivo* half-life. In this regard, attempts have been made to prepare GLP-1 analogs by causing a modification in GLP-1 thereby reducing the cleavage by DPP-4 enzyme, and to this end, GLP-1 analogs known in the art may be used without limitation.

[0029] Specifically, the substitution of the amino acid at position 8 can reduce the rate that DPP-4 enzyme inactivates GLP-1; the substitution of the amino acid at position 22 can reduce the possibility of adhesion of molecules and increase the efficacies of molecules; and the substitution of the amino acid at position 36 can reduce the risk that a fusion protein may induce a neutralizing immune response after repeated and continuous administration. Accordingly, GLP-1 analogs having an amino acid substitution at position 8, 22, or 36, respectively, may be used, although not limited thereto. Additionally, as disclosed in U.S. Pat. No. 7,452,966 B2, etc., analogs which have an amino acid substitution at position 33, 34, or 37, respectively, may be used.

[0030] In a more specific embodiment, the GLP-1 analogs may be preferably those which has a modification on the region cleaved by DPP-4 enzyme. DPP-4 enzyme cleaves GLP-1 in between amino acids at positions 8 and 9, and thus, the GLP-1 analogs in which alanine (A), the amino acid at position 8, is substituted with glycine (G) or valine (V), can reduce the cleavage by DPP-4 enzyme.

[0031] Additionally, the GLP-1 analogs may be those in which glycine (G), the amino acid at position 22, is substituted with glutamic acid (E); or arginine (R), the amino acid at position 36, is substituted with glycine (G).

[0032] Accordingly, preferably, the GLP-1 analogs may be those having the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, in which the amino acids at

position 8, 22, and/or 36 of GLP-1 (7-37) are substituted; or may be those having the amino acid sequence of SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24, in which the amino acids at position 8, 22, and/or 36 of GLP-1 (7-36) are substituted. Additionally, more preferably, the GLP-1 analogs may be those having the amino acid sequence of SEQ ID NO: 2, 3, 6, 7, 8, 9, 11, 12, 14, 15, 18, 19, 20, 21, 23, or 24, in which the amino acid at position 8, the cleavage site by DPP-4 enzyme, is modified, and most preferably, a GLP-1 analog having the amino acid sequence of SEQ ID NO: 2, in which alanine (A), the amino acid at position 8, is substituted with glycine (G). The GLP-1 analog having the amino acid sequence of SEQ ID NO: 2 may be encoded by the nucleic acid sequence of SEQ ID NO: 34. In an exemplary embodiment of the present invention, the efficacy was confirmed using the GLP-1 analog which has the amino acid sequence of SEQ ID NO: 2. The positions of modifications in the GLP-1 analogs are summarized in Table 1 below.

[Table 1]

GLP-1 (7-37)		GLP-1 (7-36)	
SEQ ID NO	Position of modification	SEQ ID NO	Position of modification
2	A8G	14	A8G
3	A8V	15	A8V
4	G22E	16	G22E
5	R36G	17	R36G
6	A8G G22E	18	A8G G22E
7	A8V G22E	19	A8V G22E
8	A8G R36G	20	A8G R36G
9	A8V R36G	21	A8VR36G
10	G22E R36G	22	G22E R36G
11	A8G G22E	23	A8G G22E
	R36G		R36G
12	A8V G22E	24	A8V G22E
	R36G		R36G

[0033] As used herein, the term "glucagon-like peptide-2 (GLP-2)" refers to a peptide hormone having 33 short amino acids (of SEQ ID NO: 44), which is generated through enzyme cleavage by an intestinal enzyme after being produced in the intestinal endocrine L cells, the secretory cells in the intestine and particular brain domains in the form of a precursor of glucagon. GLP-2 reacts to nutrient ingestion along with food intake and is co-secreted with GLP-1, oxyntomodulin, and glicentin.

[0034] GLP-2 has been widely known to be effective not only for inflammatory bowel disease but also for short bowel syndrome (SBS), etc. In fact, Gattex® (teduglutide), a GLP-2 analog, was developed by NPS pharmaceuticals, Inc. (USA) at the end of 2012, approved as an

orphan drug for the treatment of short bowel syndrome (SBS), and after expanding indications, it is currently in clinical phase 2 studies among patients with inflammatory bowel disease.

[0035] GLP-2 is secreted as a 33-amino acid-peptide and can be cleaved by DPP-4 enzyme, as is the case with GLP-1. Specifically, since GLP-2 is very rapidly cleaved by DPP-4 enzyme at the amino acid at position 2, i.e., alanine (A), and thereby generates an inactive human GLP-2, it had a limitation to be developed as a drug due to the short *in-vivo* half-life. Accordingly, there has also been an attempt to prepare GLP-2 analogs by causing a modification in GLP-2 thereby reducing the cleavage by DPP-4 enzyme, and to this end, GLP-2 analogs known in the art may be used without limitation.

[0036] Specifically, the substitution of the amino acid at position 2 can reduce the rate that DPP-4 enzyme inactivates GLP-2. That is, GLP-2 analogs, which have an amino acid substitution at position 2 from alanine (A) to glycine (G), serine (S), or valine (V), can reduce the cleavage by DPP-4 enzyme. Additionally, in another embodiment, the GLP-2 analog disclosed in U.S. Patent Application Publication No. 2007/0117752 A1 may be used. Specifically, the substitutions may include the amino acid substitution at position 2; additional amino acid substitutions at positions 3, 5, 7, 10, and 11, and/or deletion of amino acids at positions from 31 to 33, and/or addition of a stabilizing peptide sequence at the N-terminus or C-terminus, along with amino acid substitutions at positions 8, 16, 24, and 28. More specifically, alanine (A), the amino acid at position 2, may be substituted with glycine (G), serine (S), or valine (V); aspartic acid (D), the amino acid at position 3, with glutamic acid (E); serine (S), the amino acid at position 5, with threonine (T); phenylalanine (F), the amino acid at position 6, with proline (P); serine (S), the amino acid at position 7, with threonine (T); aspartic acid (D), the amino acid at position 8, with serine (S); glutamic acid (E), the amino acid at position 9, with aspartic acid (D); methionine (M), the amino acid at position 10, with leucine (L), norleucine (Nle), or an oxidation-stable Met-substituted amino acid; asparagine (N), the amino acid at position 11, with alanine (A), lysine (K), or serine (S); threonine (T), the amino acid at position 12, with lysine (K); isoleucine (I), the amino acid at position 13, with glutamic acid (E) or glutamine (Q); leucine (L), the amino acid at position 14, with methionine (M) or norleucine (Nle); aspartic acid (D), the amino acid at position 15, with glutamic acid (E); asparagine (N), the amino acid at position 16, with alanine (A); leucine (L), the amino acid at position 17, with glutamic acid (E); alanine (A), the amino acid at position 19, with threonine (T); arginine (R), the amino acid at position 20, with lysine (K); aspartic acid (D), the amino acid at position 21, with isoleucine (I); asparagine (N), the amino acid at position 24, with alanine (A) or glutamic acid (E); glutamine (Q), the amino acid at position 28, with alanine (A) or asparagine (N); isoleucine (I), the amino acid at position 31, with proline (P) or deleted; threonine (T), the amino acid at position 32, may be deleted; and aspartic acid (D), the amino acid at position 33, may be substituted-with asparagine (N) or deleted.

[0037] Various modifications described above may be applied to GLP-2, not limited thereto, and most preferably, the GLP-2 may be a GLP-2 analog having the amino acid sequence of SEQ ID NO: 45, in which alanine (A), the amino acid at position 2, is substituted with glycine (G); or a GLP-2 analog having the amino acid sequence of SEQ ID NO: 46, in which alanine

(A), the amino acid at position 2, is substituted with valine (V). The GLP-2 analog having the amino acid sequence of SEQ ID NO: 45 may be encoded by the nucleic acid sequence of SEQ ID NO: 51.

[0038] Acknowledging that GLPs (GLP-1 or GLP-2) or analogs thereof cannot be appropriately used as therapeutic drugs because they are rapidly cleaved by DPP-4 enzyme and become inactive *in-vivo*, the present inventors, in an attempt to solve the problem, have developed an immunoglobulin Fc polypeptide suitable for GLP-1 or GLP-2 and subsequently prepared a fusion polypeptide by fusing them together. Specifically, they have attempted to significantly increase *in-vivo* half-life of a GLP-1 or GLP-2 thereby enabling a GLP-1 or GLP-2 to continuously exhibit drug efficacies *in-vivo*. Additionally, they have developed fusion polypeptides having excellence in the aspects of serum stability, DPP-4 resistance, pharmacodynamic profiles, etc.

[0039] For this purpose, the present invention aims at preparing a fusion polypeptide by fusing the hyFc5 (hFc-5), prepared in International Publication No. WO 2008/147143 according to the immunoglobulin hybrid Fc technology, to the GLP-1 or GLP-2. As used herein, the term "hybrid" refers to sequences encoding two or more immunoglobulin Fc fragments of different origins are present in a single-chain immunoglobulin Fc region. The hyFc5, which is a hyFc including an IgD hinge region with a length of 30 amino acids, showed a significant increase in half-life when applied to large proteins, but the effect was much reduced when applied to relatively short peptides, for example, to the GLP-1 or GLP-2 of the present invention, and in this regard, the fusion polypeptide with improved effect of the present invention was prepared.

[0040] As used herein, the term "immunoglobulin Fc fragment" or "immunoglobulin Fc" refers to a protein, which includes a heavy-chain constant region (CH) but not the variable regions of the heavy and light chains of an immunoglobulin and the light-chain constant region (CL). The Fc may further include a hinge region, and for the purpose of the present invention, may include the heavy-chain constant region 2 (CH2) and the heavy-chain constant region 3 (CH3), but may or may not include the heavy-chain constant region (CH1).

[0041] The immunoglobulin Fc fragment of the present invention may include the hinge region, the CH2 domain region, and the CH3 domain region, from the N-terminus to the C-terminus. Specifically, the immunoglobulin Fc fragment of the present invention may be a hybrid immunoglobulin Fc fragment. Accordingly, the hinge region may include human Ig hinge region, the CH2 domain region may include the amino acid residues of human IgD and IgG4 CH2 domains, and the CH3 domain may include the amino acid residues of human IgG4 CH3 domain.

[0042] The immunoglobulin Fc polypeptide, which is suitable for the GLP or analogs thereof of the present invention, are characterized by including an IgD hinge region with a length of 35 to 49 amino acids. The hinge region basically serves to maintain flexibility when it binds to a biological active molecule such as GLP-1 or GLP-2, thereby maintaining the structure. Specifically, the hinge region may be an isolated IgD hinge region having an amino acid

sequence of 35 to 49 consecutive amino acids from the C-terminus to the N-terminus of SEQ ID NO: 25 (encoded by the nucleic acid sequence of SEQ ID NO: 36), in the amino acid sequence of SEQ ID NO: 25 of the IgD hinge region. Additionally, preferably, the hinge region may be an IgD hinge region having an amino acid sequence of 35 to 40 consecutive amino acids from the C-terminus to the N-terminus of SEQ ID NO: 25, more preferably, an IgD hinge region having an amino acid sequence of 35 to 40 consecutive amino acids, and even more preferably, an amino acid sequence of 40 consecutive amino acids. In the amino acid sequence of SEQ ID NO: 25, the IgD hinge region consisting of an amino acid sequence of 35 consecutive amino acids was indicated as SEQ ID NO: 26, the IgD hinge region consisting of an amino acid sequence of 40 consecutive amino acids as SEQ ID NO: 27, the IgD hinge region consisting of an amino acid sequence of 49 consecutive amino acids as SEQ ID NO: 28, the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 26 as SEQ ID NO: 37, the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 27 as SEQ ID NO: 38, and the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 28 as SEQ ID NO: 39, respectively.

[0043] The CH2- and CH3 domains of the immunoglobulin Fc being conjugated to the IgD hinge region may be used without limitation as long as they do not alter pharmacokinetic and drug efficacies of the fusion polypeptide of the present invention, or they do not cause any cytotoxicity such as ADCC and/or CDC, and preferably, the CH2- and CH3 domains of the hybrid Fc of the present invention. Specifically, the CH2- and CH3 domains consisting of amino acid sequences encoded by the amino acid sequence of SEQ ID NO: 29 or the nucleic acid sequence of SEQ ID NO: 40 may be used.

[0044] The GLP or analogs thereof and an immunoglobulin Fc polypeptide including the IgD hinge region and the CH2- and CH3 domains are conjugated and thereby the fusion polypeptide of the present invention can be constituted.

[0045] For example, when GLP-1 is included in the fusion polypeptide of the present invention, the fusion polypeptide may be one consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 to 32, and more specifically, one consisting of an amino acid sequence of SEQ ID NO: 30 or 31, or one consisting of an amino acid sequence of SEQ ID NO: 31, although not limited thereto. The amino acid sequence of SEQ ID NO: 30 is in a form where the GLP-1 analog of SEQ ID NO: 2 of the present invention, the IgD hinge region of SEQ ID NO: 26, and the CH2- and CH3 domains of SEQ ID NO: 29 are conjugated to each other, and is indicated as "GLP-1-hyFc8". The amino acid sequence of SEQ ID NO: 31 is in a form where the GLP-1 analog of SEQ ID NO: 2 of the present invention, the IgD hinge region of SEQ ID NO: 27, and the CH2- and CH3 domains of SEQ ID NO: 29 are conjugated to each other, and is indicated as "GLP-1-hyFc9". The amino acid sequence of SEQ ID NO: 32 is in a form where the GLP-1 analog of SEQ ID NO: 2 of the present invention, the IgD hinge region of SEQ ID NO: 28, and the CH2- and CH3 domains of SEQ ID NO: 29 are conjugated to each other, and is indicated as "GLP-1-hyFc11".

[0046] Additionally, in another exemplary embodiment of the present invention, when GLP-2 is

included in the fusion polypeptide of the present invention, the fusion polypeptide may be one consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 47 to 49, and more specifically, one consisting of an amino acid sequence of SEQ ID NO: 48 or 49, or one consisting of an amino acid sequence of SEQ ID NO: 49, although not limited thereto. The amino acid sequence of SEQ ID NO: 47 is in a form where the GLP-2 analog of SEQ ID NO: 45 of the present invention, the IgD hinge region of SEQ ID NO: 26, and the CH2- and CH3 domains of SEQ ID NO: 29 are conjugated to each other, and is indicated as "GLP-2-hyFc8". The amino acid sequence of SEQ ID NO: 48 is in a form where the GLP-2 analog of SEQ ID NO: 45 of the present invention, the IgD hinge region of SEQ ID NO: 27, and the CH2- and CH3 domains of SEQ ID NO: 29 are conjugated to each other, and is indicated as "GLP-2-hyFc9". The amino acid sequence of SEQ ID NO: 49 is in a form where the GLP-2 analog of SEQ ID NO: 45 of the present invention, the IgD hinge region of SEQ ID NO: 28, and the CH2- and CH3 domains of SEQ ID NO: 29 are conjugated to each other, and is indicated as "GLP-2-hyFc11".

[0047] In an exemplary embodiment of the present invention, GLP-1 -hyFc5 was first prepared by conjugating the hyFc5, which includes the IgD hinge region consisting of a 30 amino acid sequence developed previously by the present inventors, to a GLP-1 (FIG. 1). The half-life of GLP-1-hyFc5 was shown to increase when compared with that of the conventional peptide with GLP-1 alone. However, it was confirmed that the effect of half-life increase shown when the hyFc5 was applied to a GLP-1, which is a short peptide, was not as high as the effects exhibited when the hyFc5 was applied to a large protein.

[0048] Accordingly, the present inventors, while endeavoring to find an immunoglobulin Fc polypeptide which shows an improved efficacy compared to that of the hyFc5 when applied to a GLP-1, have discovered that, in the case of a short peptide such as a GLP-1 or a GLP-2, the increase of hinge region length enables the preparation of a fusion polypeptide having excellent activity along with excellent half-life. That is, there is a protease-sensitive cleavage site vulnerable to protease degradation in the IgD hinge region, and when the size of the physiological protein to be conjugated to the immunoglobulin Fc polypeptide was big the cleavage site was not exposed thus causing no problems. However, in the case of a short peptide such as the GLP-1 or GLP-2, the cleavage site was exposed and thus there was no sufficient increase in half-life as expected. Nevertheless, it was confirmed that the increase in hinge region length could solve the problem.

[0049] As such, in an exemplary embodiment of the present invention, hyFc9, which includes an IgD hinge region consisting of a 40 amino acid sequence, was prepared (FIG. 2). Based on this, the hyFc8 including an IgD hinge region consisting of a 35 amino acid sequence and the hyFc11 including an IgD hinge region consisting of a 49 amino acid sequence were prepared, and finally, GLP-1-hyFc9-, GLP-1-hyFc8-, and GLP-1-hyFc11 fusion polypeptides were prepared. Additionally, as the measurement result of the PK profiles of the thus-prepared fusion polypeptides of the present invention, these fusion polypeptides were shown to have significantly improved half-lives compared to that of the peptide with GLP-1 alone, and even compared to that of GLP-1-hyFc5 (FIGS. 5 and 6), and thus they were expected to show more

effective drug efficacies.

[0050] Additionally, when GLP-1-hyFc9, as the representative fusion polypeptide among the fusion polypeptides, was compared in various effects to that of the conventional GLP-1-hyFc5, GLP-1-hyFc9 was shown to be excellent in all aspects including serum stability (FIG. 7), DPP-4 resistance (FIG. 8), and PD profile (FIG. 9). Additionally, GLP-1-hyFc9 was also shown to be excellent regarding the effect of reducing body weight (FIG. 10).

[0051] Additionally, in an exemplary embodiment of the present invention, when GLP-1-hyFc9 was compared regarding the effect of ADCC inhibition compared to that of GLP-1-linker-IgG4-mut (U.S. Pat. No. 7,452,966 B2), it was confirmed that GLP-1-hyFc9 has a higher effect of ADCC inhibition than GLP-1-linker-IgG4-mut (FIG. 11). In fact, although GLP-1-linker-IgG4-mut was the one in which modifications were applied to some amino acids of an immunoglobulin Fc for the purpose of preventing ADCC, GLP-1-hyFc9 of the present invention was shown to have much higher inhibitory activity against ADCC.

[0052] Additionally, in an exemplary embodiment of the present invention, fusion polypeptides were prepared for GLP-2, in the same manner as in GLP-1. Specifically, GLP-2-hyFc9 including an IgD hinge region consisting of a 40 amino acid sequence was prepared (FIG. 3), and based on this, the GLP-2-hyFc8 including an IgD hinge region consisting of a 35 amino acid sequence and the GLP-2-hyFc11 including an IgD hinge region consisting of a 49 amino acid sequence were prepared. GLP-2-hyFc9 among the thus-prepared fusion polypeptides was shown to have an increased half-life compared to that of the GLP-2-hyFc5 (Examples 2 to 4).

[0053] Additionally, in another exemplary embodiment of the present invention, the various biological activities of GLP-2-hyFc9 were examined, and as a result, it was confirmed that GLP-2-hyFc9 does not reduce cAMP activity, which can reduce inflammation (FIG. 12), and was shown to have excellent effects of treating inflammatory bowel disease (FIG. 13), inducing the proliferation of intestinal epithelial cells (FIG. 14), promoting the growth of small intestine (FIG. 15), reducing diarrhea and lethality (FIGS. 16 and 17), etc. In particular, GLP-2-hyFc9 was shown to maintain excellent effect even with a lesser amount compared to that of the comparison group.

[0054] In conclusion, it is evident from the foregoing results, that the fusion polypeptides of the present invention have increased half-lives compared to those of the conventional GLP-1 or GLP-2, and in particular, the fusion polypeptides including the GLP-1 have excellent hypoglycemic effect, body weight reducing effect, and resistance to DPP-4 enzyme and thus they can be effectively used for treating diabetes, whereas the fusion polypeptides including the GLP-2 have an intestinotrophic effect and thus can be effectively used for treating inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, etc.

[0055] Accordingly, in another aspect, the present invention provides a pharmaceutical

composition for treating diabetes containing the fusion polypeptide as an active ingredient, and a pharmaceutical composition for treating inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide as an active ingredient.

[0056] In particular, the diabetes may be type 2 diabetes, and the inflammatory bowel disease may be ulcerative colitis or Crohn's disease.

[0057] Additionally, the endoenteritis or diarrhea may be induced by anticancer chemotherapy, and in particular, the anticancer chemotherapy may include any chemotherapy without limitation as long as the chemotherapy can induce endoenteritis or diarrhea, e.g., 5-fluorouracil (5-FU), irinotecan, leucovorin, oxaliplatin, etc.

[0058] In an exemplary embodiment, the fusion polypeptide of the present invention may be effectively used for treating diabetes by containing GLP-1 or analogs thereof, which have been known as a therapeutic agent for treating diabetes. Additionally, due to the increased half-life, excellent hypoglycemic effect, and increased resistance to DPP-4 enzyme, the fusion polypeptide of the present invention has improved drug profiles compared to those of conventional drugs and thus can be applied to pharmaceutical drugs.

[0059] Additionally, in another exemplary embodiment, the fusion polypeptide of the present invention may be effectively used for treating inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome by containing GLP-2 or analogs thereof, which have been known as a therapeutic agent for treating inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, and due to the increased half-life, it has excellent drug profiles compared to those of conventional drugs, it thus can be applied to pharmaceutical drugs.

[0060] The fusion polypeptide of the present invention may be used for treating a wide variety of diseases and symptoms.

[0061] In an exemplary embodiment, when the GLP included in the fusion polypeptide of the present invention is GLP-1, the fusion polypeptide firstly acts on receptors called "GLP-1 receptors" and thereby exhibits biological effects. Accordingly, subjects, which have diseases and/or symptoms that friendly respond to the stimulation of GLP-1 receptors or administration of GLP-1 compounds may be treated using the fusion polypeptide of the present invention. These subjects are called "require the treatment by GLP-1 compounds" or "need the stimulation of GLP-1 receptors". The subjects who have non-insulin-dependent diabetes, insulin-dependent diabetes, apoplexy (see WO 00/16797), myocardial infarction (see WO 98/08531), obesity (see WO 98/19698), changes after surgery (see U.S. Pat. No. 6,006,753), functional dyspepsia and irritable bowel syndrome (see WO 99/64060) are included. The subjects (see WO 00/07617) requiring preventative treatment by GLP-1 compounds, for example, those who have the risk of having the non-insulin-dependent diabetes are also included. The subjects who have damaged glucose resistance, damaged fast glucose, those

whose body weight accounts for about 25% or more relative to the normal body weight regarding the height and size of the subjects, those who have received a partial pancreatectomy, those who have at least one parent with non-insulin-dependent diabetes, those who have had gestational diabetes, and those who have had acute or chronic pancreatitis have the risk of developing non-insulin-dependent diabetes.

[0062] Additionally, in another exemplary embodiment, when the GLP included in the fusion polypeptide of the present invention is GLP-2, the fusion polypeptide may be used to treat and prevent gastrointestinal disorders, for example, for the treatment of osteoporosis, DPP-4 mediated symptoms, newborn infants with damaged intestinal functions, etc. Examples of the gastrointestinal disorders may include ulcer, gastritis, dyspepsia syndrome, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, gluten-induced enteropathy or celiac sprue occurred from chronic dyspepsia, tropical sprue, hypogammaglobulinemia sprue, gastroenteritis, local gastroenteritis (Crohn's disease), ulcerative colitis, diarrhea-associated irritable bowel syndrome, injury of small bowel, short bowel syndrome, endoenteritis caused by anticancer chemotherapy and diarrhea caused by anticancer chemotherapy, etc. Additionally, other symptoms, such as gastroenteritis due to radiation, inflammatory gastroenteritis or gastroenteritis after inflammation, and injury of small bowel by toxic materials or other chemotherapies, may be included.

[0063] The effective amount of the fusion polypeptide described in the present invention is the amount that can bring about the intended effects of treatment and/or prevention while not inducing unacceptable adverse effects, when the fusion polypeptide is administered to a subject in need of the stimulation of GLP-1 or GLP-2 receptor. The "intended effect" includes at least one described below: 1) reduction of disease(s) or associated symptom(s) thereof; 2) delay of initiation of signs associated with disease(s) or symptom(s); 3) an increase of life-expectancy compared to that without treatment; and 4) higher quality-life compared to that without treatment. For example, the "effective amount" of the fusion polypeptide of the present invention refers to the amount that can cause a delay in the occurrence of diabetic complications, such as retinopathy, neuropathy, and renal disease, by causing a larger control of blood glucose levels compared to that of the untreated case. The "effective amount" of the fusion polypeptide of the present invention for preventing diabetes refers to the amount that can delay the occurrence of a disease at the increased blood glucose level requiring the treatment with anti-hypoglycemic drugs, such as sulfonyl, urea, thiazolidinedione, insulin and/or bisguanidine, compared to that of the untreated case.

[0064] In an exemplary embodiment of the present invention, the fusion polypeptide of the present invention was confirmed to also have excellent drug efficacy for treating diabetes, in addition to the experiment which confirmed the PK profiles confirmed by half-life. Specifically, when the pharmacodynamic (PD) profile of GLP-1-hyFc9 fusion polypeptide was examined in an *in-vivo* experiment, GLP-1-hyFc9 fusion polypeptide was shown to have much higher hypoglycemic effect compared to that of GLP-1-hyFc5 (FIG. 9), and also in an *in-vitro* experiment, GLP-1-hyFc9 fusion polypeptide was shown to have significantly higher resistance to DPP-4 enzyme thus confirming that GLP-1-hyFc9 fusion polypeptide has excellent effect

with regard to stability to DPP-4 enzyme (FIG. 8). It is thus evident that the maintenance of blood glucose levels is important in treating diabetes, and considering that DPP-4 inhibitor is normally used as a therapeutic agent for treating diabetes, the fusion polypeptide of the present invention can be used as an excellent drug for treating diabetes.

[0065] As used herein, the term "treatment" refers to all actions that restore or beneficially change the symptoms of diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, by administering the fusion polypeptide according to the present invention or a pharmaceutical composition containing the same.

[0066] The pharmaceutical composition of the present invention may contain the fusion polypeptide at varied wt% as an active ingredient, as long as it can exhibit the therapeutic effect for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome.

[0067] Additionally, the pharmaceutical composition of the present invention may further contain appropriate carriers, excipients, or diluents according to the conventional method. Examples of the carriers, excipients, and diluents to be contained in the composition of the present invention may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc., but is not limited thereto.

[0068] The pharmaceutical composition of the present invention may be prepared according to the conventional method in a formulation type for oral administration, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols; a formulation type for external use; a formulation type for suppositories; or a formulation type for sterile injections. Specifically, the formulations may be prepared using a commonly used diluent or excipient, such as a filler, an extender, a binder, a humectant, a disintegrant, a surfactant, etc. Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, etc., and these solid formulations may be prepared by adding at least one excipient, e.g., starch, calcium carbonate, sucrose or lactose, gelatin, etc. Additionally, a lubricant such as magnesium stearate and talc may be used, in addition to a simple excipient. Examples of liquid formulations for oral administration may include suspensions, liquid medicine for internal use, emulsions, syrups, etc., and various kinds of excipients such as humectants, sweeteners, fragrances, preservatives, etc., may be contained, in addition to the frequently used simple diluents such as water and liquid paraffin. Examples of formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. For non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, an injectable ester such as ethyloleate may be used. Examples of bases for suppositories may include Witepsol, macrogol, Tween 61, cacao butter, laurinum, glycerogelatin, etc.

[0069] The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient for the treatment of diseases at a reasonable benefit/risk ratio applicable to a medical treatment without causing any adverse effects, and the level of the effective dose may be determined based on the factors including the health conditions of a patient, type of disease(s), severity of illness, drug activity, drug sensitivity, administration method, administration time, administration route and excretion rate, length of treatment, factors including drug(s) to be mixed or concurrently used in combination, and other factors well known in the medical field.

[0070] Additionally, the pharmaceutical composition of the present invention may be administered alone or in combination with other therapeutic agent(s), which exhibit(s) therapeutic effects for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome. The pharmaceutical composition of the present invention may be administered in various routes to mammals including rats, mice, cattle, humans, etc. The administration means the introduction of a particular material to a patient by an appropriate manner, and the composition may be administered via any of the common routes as long as the composition can arrive at a target tissue. For example, administration may be performed intra-articularly, intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, intrapulmonarily, intrarectally, etc., but is not limited thereto.

[0071] The fusion polypeptide of the present invention is preferably administered once in four weeks, once in two weeks, or once a week. The fusion polypeptide may be more frequently administered according to the diseases to be treated, e.g., twice or three times a week.

[0072] In another aspect, the present invention provides a polynucleotide encoding the fusion polypeptide, an expression vector including the polynucleotide, and a host cell including the expression vector.

[0073] The technical feature of the present invention lies in the fusion polypeptide explained above, and the polynucleotide encoding the fusion polypeptide, the expression vector including the polynucleotide, and the host cell including the expression vector may be included within the scope of the present invention, and the type of host cell is not limited as long as the expression of the fusion polypeptide is enabled.

[0074] Although not limited thereto, the polynucleotide may be, for example, one which consists of a nucleic acid sequence of SEQ ID NO: 41 encoding 'GLP-1-hyFc8'; one which consists of a nucleic acid sequence of SEQ ID NO: 42 encoding 'GLP-1-hyFc9'; or one which consists of a nucleic acid sequence of SEQ ID NO: 43 encoding 'GLP-1-hyFc11'; and specifically, may be one which consists of a nucleic acid sequence of SEQ ID NO: 41 or SEQ ID NO: 42; or one which consists of a nucleic acid sequence of SEQ ID NO: 42.

[0075] Additionally, in another exemplary embodiment, the polynucleotide may be one which

consists of a nucleic acid sequence of SEQ ID NO: 52 encoding 'GLP-2-hyFc8'; one which consists of a nucleic acid sequence of SEQ ID NO: 53 encoding 'GLP-2-hyFc9'; or one which consists of a nucleic acid sequence of SEQ ID NO: 54 encoding 'GLP-2-hyFc11'; and specifically, may be one which consists of a nucleic acid sequence of SEQ ID NO: 53 or SEQ ID NO: 54; or one which consists of a nucleic acid sequence of SEQ ID NO: 54.

[0076] Considering the codons preferred by organisms to express the fusion polypeptide based on the codon degeneracy, various modifications on the fusion polynucleotide may be executed on the coding region within the scope not changing the amino acid sequence of the fusion polypeptide.

[Advantageous Effects of the Invention]

[0077] The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and thus it has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs. Accordingly, the fusion polypeptide of the present invention can be effectively applied to pharmaceutical drugs.

[BRIEF DESCRIPTION OF THE DRAWINGS]

[0078]

FIG. 1, being related to the preparation of GLP-1-hyFc5, shows a schematic diagram and a sequence of GLP-1-hyFc5.

FIG. 2, being related to the preparation of GLP-1-hyFc9, shows a sequence and a schematic diagram of GLP-1-hyFc5 and GLP-1-hyFc9, respectively.

FIG. 3, being related to the preparation of GLP-2-hyFc9, shows a schematic diagram of GLP-2-hyFc5 and GLP-2-hyFc9, respectively.

FIG. 4 shows a graph confirming the PK profiles of GLP-1 peptide and GLP-1-hyFc5.

FIG. 5, being related to the PK profiles of GLP-1-hyFc5 and GLP-1-hyFc9, shows the values of the areas under the curve (AUC) illustrating the amount of proteins remaining in the blood and drug concentration in each time zone.

FIG. 6, being related to the PK profiles of GLP-1-hyFc5, GLP-1-hyFc8, and GLP-1-hyFc9, shows the amount of proteins remaining in the blood in each time zone.

FIG. 7, being related to the confirmation of serum stability of GLP-1-hyFc5 and GLP-1-hyFc9, shows the values of the areas under the curve (AUC) of a graph illustrating the amount of

proteins remaining in the blood in each time zone.

FIG. 8, being related to the confirmation of DPP-4 resistibility of GLP-1-hyFc5 and GLP-1-hyFc9, shows the values of the areas under the curve (AUC) of a graph illustrating the amount of proteins remaining in the blood in each reaction time zone.

FIG. 9, being related to the confirmation of PD profiles of GLP-1-hyFc5 and GLP-1-hyFc9, shows the AUC values obtained by measuring the change in glucose concentration in the blood as AUC content % relative to that of negative control.

FIG. 10, being related to the confirmation of body weight loss effect of GLP-1-hyFc9, shows the amount of body weight change and the cumulative food intake.

FIG. 11, being related to the comparison results of ADCC-inhibitory effects of GLP-1-hyFc9 and GLP-1-linker-IgG4-mut, confirms their binding capabilities to Fcγ receptors.

FIG. 12, being related to the confirmation of *in-vitro* biological activities of GLP-2, GLP-2-hyFc5, and GLP-2-hyFc9, shows the measurement results of membrane depolarization induced by cAMP.

FIG. 13, being related to the therapeutic effects of GLP-2-2G and GLP-2-hyFc9 on inflammatory bowel disease, shows the changes in body weight, amount of TNF-α expression, and length of small intestine in an experimental model induced with inflammatory bowel disease by Indomethacin administration.

FIG. 14 confirms the effects of GLP-2-2G and GLP-2-hyFc9 on inducing the proliferation of intestinal epithelial cells.

FIG. 15, being related to the confirmation of the effect of GLP-2-hyFc9 on the growth promotion of small intestine, shows the weight of small intestine.

FIG. 16, being related to the confirmation of the effect of GLP-2-hyFc9 on the reduction of diarrhea induced by 5-FU.

FIG. 17, being related to the confirmation of the effect of GLP-2-hyFc9 on the reduction of lethality, shows the decreased morbidity rate occurred due to the induction of diarrhea by 5-FU.

[DETAILED DESCRIPTION OF THE INVENTION]

[0079] Hereinafter, the present invention will be described in more detail with reference to the following Examples. However, these Examples are for illustrative purposes only, and the invention is not intended to be limited by these Examples.

Example 1: Preparation of GLP-hyFc fusion protein

1-1: Preparation of GLP-1-hyFc5, GLP-1-hyFc9, GLP-1-hyFc8, and GLP-1-hyFc11

[0080] Although glucagon like peptide-1 (GLP-1) is a protein effective for the treatment of diabetes, it had many limitations to be developed as a drug because it is very rapidly cleaved *in-vivo* by DPP-4 enzyme and has a very short half-life of about 3 to 5 minutes, and thus many attempts have been made to increase *in-vivo* half-life.

[0081] As such, in order to reduce the cleavage by DPP-4 enzyme, a GLP-1 analog was prepared based on GLP-1 (7-37) by substituting alanine, the amino acid at position 8, which is the cleavage site for DPP-4 enzyme, with glycine (SEQ ID NO: 2). Then, GLP-1-hyFc5 fusion polypeptide was prepared by fusing the hybrid Fc 5 (hyFc5) polypeptide, which was previously prepared in International Patent Publication No. WO 2008-147143 by the present inventors, to the GLP-1 analog peptide (FIG. 1). The entire sequence of GLP-1-hyFc5 fusion polypeptide is shown in FIG. 1.

[0082] Additionally, in the present invention, it was attempted to prepare a fusion polypeptide having excellent activities in other aspects while further increasing the half-life compared to that of GLP-1-hyFc5.

[0083] Specifically, it was attempted to prepare a fusion polypeptide having excellent activities while having an improved half-life by variously controlling the IgD hinge region of hyFc5, and it was confirmed that the increase of the number of amino acids at the IgD hinge region could satisfy these conditions.

[0084] Accordingly, hyFc9 (FIG. 2), which has a hinge region consisting of 40 amino acids (SEQ ID NO: 27) was first prepared by increasing the number of amino acids in the hinge region of the hyFc5, which has a hinge region consisting of 30 amino acids, and then the hyFc8, which has a hinge region consisting of 35 amino acids (SEQ ID NO: 26), and the hyFc11, which has a hinge region consisting of 49 amino acids (SEQ ID NO: 28) were prepared, respectively. Additionally, GLP-1-hyFc9 (SEQ ID NO: 31), GLP-1-hyFc8 (SEQ ID NO: 30), and GLP-1-hyFc11 (SEQ ID NO: 32) fusion polypeptides were prepared by conjugating the GLP-1 analog peptide to each of hyFc9, the hyFc8, and the hyFc11, respectively.

1-2: Preparation of GLP-2-hyFc5, GLP-2-hyFc9, GLP-2-hyFc8, and GLP-2-hyFc11

[0085] As is the case with GLP-1, glucagon like peptide-2 (GLP-2) also had many limitations to be developed as a drug because it is very rapidly cleaved *in-vivo* by DPP-4 enzyme and has a very short half-life of about 7 minutes. In order to increase the *in-vivo* half-life of GLP-2, alanine, the amino acid at position 2, which is the cleavage site for DPP-4 enzyme, is

substituted with glycine (GLP-2-2G peptide, SEQ ID NO: 45). Although the substituted GLP-2-2G peptide is prepared in a once-daily formulation for treating short bowel syndrome in adults, it is still necessary to develop a GLP-2 analog having a much longer half-life than the substituted GLP-2-2G peptide, considering that short bowel syndrome should be treated continuously. For this purpose, GLP-2-hyFc5 fusion polypeptide was prepared by fusing the hyFc5 polypeptide, which was previously prepared in International Patent Publication No. WO 2008-147143 by the present inventors, to GLP-2-2G analog peptide (FIG. 3). Additionally, it was attempted to prepare a fusion polypeptide having excellent activities while having an improved half-life by variously controlling the IgD hinge region with the entire length of 64 amino acids. Specifically, hyFc9, which has a hinge region consisting of 40 amino acids, was prepared by increasing the amino acids in the hinge region of the hyFc5, which has a hinge region consisting of 30 amino acids, and then GLP-2-hyFc9 fusion polypeptide was prepared by conjugating GLP-2-2G peptide thereto (FIG. 3, SEQ ID NO: 48). Additionally, the hyFc8, which has a hinge region consisting of 35 amino acids, and the hyFc11, which has a hinge region consisting of 49 amino acids, were prepared, and then GLP-2-hyFc8 (SEQ ID NO: 47) and GLP-2-hyFc11 (SEQ ID NO: 49) fusion polypeptides were prepared by conjugating GLP-2-2G peptide to each of them.

Example 2: Confirmation of PK profile of GLP-hyFc fusion protein

2-1: Confirmation of PK profile of GLP-1-hyFc5

[0086] In order to confirm the pharmacokinetic profile (PK profile) of the thus-prepared GLP-1-hyFc5 fusion polypeptide, experiments were performed as follows using the synthesized GLP-1 as a control.

[0087] Male Sprague Dawley rats (4 rats/group) were administered intravenously with respective proteins, GLP-1 and GLP-1-hyFc5. Blood samples were collected before the administration and after the administration at 0.08-, 0.16-, 0.5-, 1-, 2-, 4-, 6-, 12-, 24-, 48-, 72-, and 96 hours, respectively. The blood samples were stored at room temperature for 30 minutes for agglutination. The samples were centrifuged at 3000 rpm for 10 minutes to obtain serum from each sample and then stored in a deep freezer. The samples were quantitated by dilution to be analyzed in a position on a straight line of standard curve using GLP-1 kit (ALPCO, Cat. No. 43-GP1HU-E01).

[0088] As a result, as shown in FIG. 4, the peptide including GLP-1 alone, which was not fused with the hyFc polypeptide, had a short half-life of 4 minutes, whereas GLP-1-hyFc5 polypeptide, which was fused with GLP-1 and hyFc5, was shown to have a half-life with about a 116-fold increase (> 8 hours).

2-2: Confirmation of PK profile GLP-1-hyFc9

[0089] The PK profile was confirmed by comparing the half-life of GLP-1-hyFc9 fusion polypeptide with that of GLP-1-hyFc5 fusion polypeptide prepared in Example 1.

[0090] Male Sprague Dawley rats (4 rats/group) were administered subcutaneously with respective proteins. Blood samples were collected before the administration and after the administration at 2-, 6-, 12-, 26-, 48-, 72-, 96-, 120-, 144-, and 168 hours, respectively. The blood samples were stored at room temperature for 30 minutes for agglutination. The samples were centrifuged at 3000 rpm for 10 minutes to obtain serum from each sample and then stored in a deep freezer. The samples were quantitated by dilution to be analyzed in a position on a straight line of standard curve using GLP-1 kit (IBL, Cat. No. 27784A).

[0091] The results were indicated in terms of protein amount remaining in the blood for each time zone and the value of the area under the curve (AUC). As shown in FIG. 5, GLP-1-hyFc9 had about a 12-fold higher AUC value compared to that of GLP-1-hyFc5. Based on these results, GLP-1-hyFc9 was confirmed to have a significantly increased half-life compared to that of GLP-1-hyFc5, and is thus expected to have more effective drug efficacy.

2-3: Confirmation of PK profile GLP-1-hyFc8

[0092] The PK profile of the GLP-1-hyFc8 fusion polypeptide was confirmed by comparing the half-life of the GLP-1-hyFc8 fusion polypeptide with that of GLP-1-hyFc9 fusion polypeptide. Experiments were performed for GLP-1-hyFc5, the GLP-1-hyFc9, and the GLP-1-hyFc8 in the same manner as in Example 2-2.

[0093] As a result, as shown in FIG. 6, GLP-1-hyFc9 and the GLP-1-hyFc8 were confirmed to have a similar level of PK profiles, and the GLP-1-hyFc8 showed a slightly higher level. These levels were shown to be much higher levels compared to that of the control, GLP-1-hyFc5. Based on these results, the GLP-1-hyFc8 was confirmed to have more effective drug efficacy with the increased half-life.

2-4: Confirmation of PK profiles of GLP-2-hyFc5 and GLP-2-hyFc9

[0094] In order to confirm the pharmacokinetic profiles (PK profiles) of the GLP-2-hyFc5 and GLP-2-hyFc9 fusion polypeptides prepared above, experiments were performed as follows.

[0095] Male Sprague Dawley rats (3 rats/group) were administered subcutaneously with respective proteins (GLP-2-2G peptide, GLP-2-hyFc5, and GLP-2-hyFc9). Blood samples were collected before the administration and after the administration at 0.08-, 0.16-, 0.5-, 2-, 4-, 8-, 24-, 48-, 96-, 120-, and 168 hours, respectively. The blood samples were stored at room temperature for 30 minutes for agglutination. The samples were centrifuged at 3000 rpm for 10

minutes to obtain serum from each sample and then stored in a deep freezer. The samples were quantitated by dilution to be analyzed in a position on a straight line of standard curve using GLP-2 kit (Millipore, Cat. No. EZGLP2-37K). As a result, the peptide including GLP-2-2G peptide alone, which was not fused with an Fc protein, had a short half-life of 1.2 hours, whereas the GLP-2-hyFc5 and GLP-2-hyFc9 fusion proteins were shown to have half-lives of 44- and 65 hours, respectively, thus showing about a 36- and 54-fold increase, compared to that of GLP-2-2G. In particular, GLP-2-hyFc9 was shown to have about a 1.5-fold increase compared to that of the GLP-2-hyFc5.

Example 3: Test of biological activity of GLP-hyFc fusion protein

3-1: Confirmation of serum stability of GLP-1-hyFc9

[0096] Additional various effects of GLP-1-hyFc9, among the fusion polypeptides with excellent PK profiles, were confirmed. GLP-1-hyFc5 was used as a comparison group. In order to confirm the stability of GLP-1-hyFc5 and GLP-1-hyFc9 on the decomposing factors in sera, the stability test was performed in rat sera.

[0097] First, two test materials were diluted with rat sera, and each sample was reacted at 37°C for 0-, 6-, 10-, 24-, and 48 hours, and each material was quantitated via ELISA assay.

[0098] The results were indicated in terms of protein amount remaining in the blood for each time zone and the value of the area under the curve (AUC). As shown in FIG. 7, GLP-1-hyFc9 had about a 1.2-fold higher AUC value compared to that of GLP-1-hyFc5. Based on these results, GLP-1-hyFc9 was confirmed to also have a significantly higher serum stability compared to that of GLP-1-hyFc5.

3-2: Confirmation of DPP-4 resistance of GLP-1-hyFc9

[0099] DPP-4 resistance test was performed in order to confirm the resistance of GLP-1-hyFc5 and GLP-1-hyFc9 to DPP-4 (Sigma, Cat No. D4943-1VL), which is a major metabolic enzyme, and the subsequent stability thereof.

[0100] Two test materials were added into a thermostat kept at 37°C, reacted for 0-, 2-, 8-, 24-, and 48 hours, and each material was quantitated.

[0101] The results were indicated in terms of protein amount remaining in the blood for each time zone and the value of the area under the curve (AUC). As shown in FIG. 8, GLP-1-hyFc9 had about a 7-fold higher DPP-4 resistance compared to that of GLP-1-hyFc5. Based on these results, GLP-1-hyFc9 was confirmed to have a significantly increased stability to DPP-4

enzyme, which can cleave GLP-1).

3-3: Confirmation of PD profile of GLP-1-hyFc9

[0102] In order to confirm the pharmacokinetic profiles (PK profiles) of GLP-1-hyFc5 and GLP-1-hyFc9, experiments were performed as follows.

[0103] CD-1 mice (10 mice/group) were administered subcutaneously with the respective proteins and then administered with glucose on day 0, 1, 2, 4, and 8 thereafter and the change in blood glucose levels was measured to confirm the hypoglycemic effect.

[0104] Regarding the result, the change in blood glucose levels was measured at each measurement date from 1 minute to 180 minutes after the glucose administration and the AUC values were obtained for each experiment day, and indicated as the AUC content (%) of GLP-1-hyFc5 and GLP-1-hyFc9 relative to the negative control (vehicle).

[0105] As a result, as shown in FIG. 9, it was confirmed that GLP-1-hyFc5 started to lose the hypoglycemic effect from the Day 2 and became normalized, whereas GLP-1-hyFc9 maintained the blood glucose levels up to the Day 8 at a low level. These results indicate that GLP-1-hyFc9 can retain hypoglycemic effect until the Day 8.

3-4: Confirmation of the weight-reducing effect of GLP-1-hyFc9

[0106] The pharmacokinetic disposition (PD, cumulative food intake & weight loss effect) of GLP-1-hyFc9 in an ob/ob disease model was confirmed relative to the negative control (vehicle).

[0107] The ob/ob mice (10 mice/group) were repeatedly administered subcutaneously once a week with the protein and the changes in body weight and cumulative food intake were measured each week. For body weight, the difference obtained by subtracting the value of change in body weight of the negative control from the value of change in body weight per group is indicated, and for cumulative food intake, likewise, the difference relative to that of the negative control is indicated (FIG. 10). Consequently, GLP-1-hyFc9 exhibited a significant effect of body weight loss and the effect of reducing food intake in terms of the change in body weight and cumulative food intake, compared to that of the negative control, and that the effects were in a dose-dependent manner.

[0108] In summary, as shown in Table 2 below, GLP-1-hyFc9 was shown to have improved effects compared to GLP-1-hyFc5.

[Table 2]

	hyFc5	hyFc9
--	-------	-------

In-vitro	Serum stability (rat)	++	+++
	DPP-4 resistibility	+	++++
In-vivo	PK study (rat)	+	++++
	IPGTT (mouse)	+	+++

3-5: Comparison of ADCC inhibitory activity with GLP-1-linker-IgG4-mut

[0109] Additionally, for GLP-1-hyFc9 fusion polypeptide exhibiting excellent effects in various aspects through examples, the superiorities were confirmed by comparing the ADCC inhibitory with that of the fusion polypeptides known in the art.

[0110] GLP-1-linker-IgG4-mut disclosed in U.S. Pat. No. 7,452,966 B2 was used as a comparison group, which is a polypeptide intended to inhibit antibody dependent cell-mediated cytotoxicity (ADCC) due to three mutations in the IgG4 region.

[0111] Since both GLP-1-linker-IgG4-mut and GLP-1-hyFc9 of the present invention structurally include the CH2-CH3 domains of the IgG4, there is no safety issue regarding complement dependent cytotoxicity (CDC) involved therein. However, for confirming the ADCC safety, the binding affinity to the Fcγ receptors, which serve an important role in inducing ADCC, and for this purpose, a test of binding affinity was performed using Surface Plasmon Resonance (SPR, Bio-rad, #Proteon XPR36).

[0112] First, ligands were immobilized by flowing Fcγ receptors into each channel of bio-rad chips, which were amine-coupled by an NHS/EDC reaction, using an acetate buffer. As the concept of the negative control, a phosphate buffered saline (PBS) containing Tween 20 was flown. Each of the chips, to which each Fcγ receptor was bound, was measured of its binding affinity by flowing each test material thereto.

[0113] As a result, as shown in FIG. 11, GLP-1-linker-IgG4-mut showed higher binding capability to major Fcγ receptors, which induce ADCC, although several amino acid sites were modified in order to remove the remaining effector functions of the immunoglobulin Fc region, compared to GLP-1-hyFc9, and for this reason, it was confirmed to have potential cytotoxicity. In contrast, GLP-1-hyFc9 showed lower binding ability with all Fcγ receptors compared to GLP-1-linker-IgG4-mut, and from this, GLP-1-hyFc9 was confirmed to be safer in the case of a long-term drug administration.

3-6: Test of inflammation-associated biological activity of GLP-2-hyFc9

[0114] Along with GLP-1-hyFc9, GLP-2-hyFc9 was subjected to a biological activity test. Since GLP-2-hyFc9, although having a significantly increased half-life, can reduce the biological activity of GLP-2-2G peptide itself due to the fusion with hyFc9, the biological activity was examined.

[0115] In order to examine the biological activity of GLP-2-hyFc9, the level of intracellular cAMP, which is increased upon the stimulation of GLP-2-hyFc9. The GLP-2R-expressing 293 cells were cultured in a 96-well in an amount of 6×10^4 cells. In 24 hours, the cells were treated with the fusion proteins at concentrations of 0 nM, 0.1 nM, 1 nM, 3 nM, 10 nM, 100 nM, and 300 nM, and the membrane depolarization induced by the increased intracellular cAMP was measured using a fluorescent membrane potential dye. As a result, as shown in FIG. 12, it was confirmed that the GLP-2-hyFc5 fusion protein was markedly reduced in its biological activity by showing an activity of 27% when the activity of GLP-2-2G peptide was set at 100%, whereas GLP-2-hyFc9 fusion protein showed an activity of 98% thus showing no reduction in its inflammation-related biological activity, even after the fusion with hyFc9.

3-7: Confirmation of the therapeutic effect of GLP-2-hyFc9 on inflammatory bowel disease

[0116] GLP-2-hyFc9 was subcutaneously administered to an inflammatory bowel disease model induced by Indomethacin and the effect of improvement was compared. Male Sprague Dawley rats (6 rats/group) were treated with Indomethacin on Day 1 and Day 2 at a concentration of 9 mg/kg to induce inflammatory bowel disease. GLP-2-2G, as a comparison group, was administered twice daily to a total of 12 times at a concentration of 50 nmol/kg from Day 3 to Day 8, whereas GLP-2-hyFc9 was administered once every two days to a total of 3 times at a concentration of 50 nmol/kg and the rats were autopsied on Day 9. The changes in the body weight, the length of small intestine, and the expression level of inflammatory cytokine (TNF- α) were compared in each group, and the therapeutic effects on the symptoms of inflammatory bowel disease were compared.

[0117] As a result, as shown in FIG. 13, the body weight and the length of small intestine were shown to significantly decrease while the expression level of inflammatory cytokine (TNF- α) increased by Indomethacin treatment. However, in the group treated with GLP-2-hyFc9 showed a lower reduction in the body weight, a decrease in the expression level of inflammatory cytokine (TNF- α), and also an increase in the length of small intestine, thus confirming the therapeutic effect of GLP-2-hyFc9 on the treatment of inflammatory bowel disease. In particular, GLP-2-hyFc9, although administered at a level of one-fourth to that of GLP-2-2G, showed a more significant effect.

3-8: Confirmation of the effect of GLP-2-hyFc on inducing the proliferation of intestinal epithelial cells

[0118] The effect of GLP-2-hyFc9 on inducing the proliferation of intestinal epithelial cells was examined. GLP-2-2G peptide was used as a comparison group. GLP-2 is known to increase the production of growth factors (IGF-1, VEGF, EGF, etc.) by acting on fibroblasts (effector cells), and the increased growth factors promote the proliferation of intestinal epithelial cells. Accordingly, an experiment was performed to confirm the effect of GLP-2-hyFc9 on inducing the proliferation of intestinal epithelial cells. CCD-18co cells were cultured in a serum-free medium for 24 hours, treated with GLP-2-2G and GLP-2-hyFc9 at concentrations of 50 nM, 100 nM, and 250 nM, and cultured for 24 hours. Caco-2 cells were treated with the cell culture medium (conditioned media; CM), cultured for 3 days, and Caco-2 cell proliferation was measured using EZ Cyttox (Dogen, Cat.No.EZ-1000). As a result, as shown in FIG. 14, the capability of GLP-2-hyFc9 of promoting Caco-2 cell proliferation was similar to that of GLP-2-2G peptide. That is, the biological activity of GLP-2, even after a fusion with hyFc9, was shown to be maintained at a level similar to that of native GLP-2.

3-9: Confirmation of the intestinotrophic effect of GLP-2-hyFc9

[0119] In order to confirm the pharmacodynamic characteristic of GLP-2-hyFc9, i.e., intestinotrophic effect, an experiment was performed as follows. Male Sprague Dawley rats (8 rats/group) were treated with GLP-2-hyFc9 once daily for 5 days at concentrations of 0 nmol/kg, 1 nmol/kg, 3 nmol/kg, 10 nmol/kg, 30 nmol/kg, 100 nmol/kg, and 300 nmol/kg, autopsied to measure the weight of their small intestine, and thereby the intestinotrophic effect of GLP-2-hyFc9 was confirmed. As shown in FIG. 15, the group treated with GLP-2-hyFc9 showed an increase of small intestine in a dose-dependent manner, and ED₅₀ was shown to be 14.2 nmol/kg/day.

3-10: Confirmation of the effect of GLP-2-hyFc9 on reducing diarrhea and lethality

[0120] Irinotecan or 5-FU, among the anticancer chemotherapy drugs used for killing cancer cells, can induce villous atrophy by destroying crypts cells, which form the villi of intestinal cells, and this may lead to fatal diarrhea. Since the villous atrophy and diarrhea induced by anticancer chemotherapy drugs may affect lethality, an experiment was performed to confirm whether the GLP-2-hyFc9 treatment can prevent diarrhea and lethality induced by anticancer chemotherapy drugs. Male Sprague Dawley rats (15 rats/group) were treated with 5-FU once daily to a total of four times at a concentration of 75 mg/kg to induce diarrhea. The rats were treated with GLP-2-hyFc a total of four times at a concentration of 80 nmol/kg/day or once at a concentration of 320 nmol/kg/day, and diarrhea score was examined for 10 days, thereby confirming lethality. As a result, as shown in FIG. 16, the group treated four times with GLP-2-hyFc9 at a concentration of 80 nmol/kg/day showed a decrease in diarrhea score compared to the untreated group, and the group treated once with GLP-2-hyFc9 at a concentration of 320 nmol/kg/day showed a significant decrease in diarrhea score compared to the group treated four times with GLP-2-hyFc9 at a low dose. Additionally, the lethality induced by 5-FU (27%)

was reduced by 20% to 6.7% in the group treated with GLP-2-hyFc9 (FIG. 17). Therefore, it was confirmed that GLP-2-hyFc9 has the effect of preventing diarrhea induced by anticancer chemotherapy.

<110> Genexine, Inc.

<120> Fusion Polypeptide Comprising GLP and Immunoglobulin Hybrid Fc and use thereof

<130> OPA15319-PCT

<150> KR 10-2014-0195793

<151> 2014-12-31

<160> 54

<170> KopatentIn 2.0

<210> 1

<211> 31

<212> PRT

<213> Homo sapiens

<400> 1

```

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1           5           10          15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
          20          25          30

```

<210> 2

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8G)

<400> 2

```

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1           5           10          15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
          20          25          30

```

<210> 3

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8V)

<400> 3

His Val Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
 20 25 30

<210> 4

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (G22E)

<400> 4

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
 20 25 30

<210> 5

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (R36G)

<400> 5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly
 20 25 30

<210> 6

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8G/G22E)

<400> 6

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
 20 25 30

<210> 7

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8V/G22E)

<400> 7

His	Val	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg	Gly	
			20					25					30		

<210> 8

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8G/R36G)

<400> 8

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly	Gly	
			20					25					30		

<210> 9

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8V/R36G)

<400> 9

His	Val	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly	Gly	
			20					25					30		

<210> 10

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (G22E/R36G)

<400> 10

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly	Gly	
			20					25					30		

<210> 11

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8G/G22E/R36G)

<400> 11

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly	Gly	
			20					25					30		

<210> 12

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8V/G22E/R36G)

<400> 12

His	Val	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly	Gly	
			20					25					30		

<210> 13

<211> 30

<212> PRT

<213> Homo sapiens

<400> 13

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg		
			20					25					30		

<210> 14

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8G)

<400> 14

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg		
			20					25					30		

<210> 15

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8V)

<400> 15

His	Val	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg
			20					25					30

<210> 16

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (G22E)

<400> 16

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg
			20					25					30

<210> 17

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (R36G)

<400> 17

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly
			20					25					30

<210> 18

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8G/G22E)

<400> 18

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
 20 25 30

<210> 19

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8V/G22E)

<400> 19

His Val Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
 20 25 30

<210> 20

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8G/R36G)

<400> 20

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly
 20 25 30

<210> 21

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8V/R36G)

<400> 21

His Val Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly
 20 25 30

<210> 22

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (G22E/R36G)

<400> 22

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly
			20					25					30

<210> 23

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8G/G22E/R36G)

<400> 23

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly
			20					25					30

<210> 24

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1(7-36) analogue (A8V/G22E/R36G)

<400> 24

His	Val	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Glu
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Gly
			20					25					30

<210> 25

<211> 64

<212> PRT

<213> Homo sapiens

<400> 25

Arg	Trp	Pro	Glu	Ser	Pro	Lys	Ala	Gln	Ala	Ser	Ser	Val	Pro	Thr	Ala
1				5					10					15	

Gln	Pro	Gln	Ala	Glu	Gly	Ser	Leu	Ala	Lys	Ala	Thr	Thr	Ala	Pro	Ala
			20					25					30		

Thr	Thr	Arg	Asn	Thr	Gly	Arg	Gly	Gly	Glu	Glu	Lys	Lys	Lys	Glu	Lys
		35					40					45			

Glu	Lys	Glu	Glu	Gln	Glu	Glu	Arg	Glu	Thr	Lys	Thr	Pro	Glu	Cys	Pro
	50						55				60				

<210> 26
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 26
 Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys
 1 5 10 15
 Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro
 20 25 30
 Glu Cys Pro
 35

<210> 27
 <211> 40
 <212> PRT
 <213> Homo sapiens

<400> 27
 Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly
 1 5 10 15
 Gly Glu Glu Lys Lys Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg
 20 25 30
 Glu Thr Lys Thr Pro Glu Cys Pro
 35 40

<210> 28
 <211> 49
 <212> PRT
 <213> Homo sapiens

<400> 28
 Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro
 1 5 10 15
 Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu
 20 25 30
 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys
 35 40 45
 Pro

<210> 29
 <211> 215
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgD & IgG4 Hybrid CH2 &CH3 region

<400> 29
 Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro Pro Lys Pro Lys
 1 5 10 15

```

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
      20              25              30

Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
      35              40              45

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
      50              55              60

Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
      65              70              75              80

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
      85              90              95

Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
      100             105             110

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
      115             120             125

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
      130             135             140

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
      145             150             155             160

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
      165             170             175

Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
      180             185             190

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
      195             200             205

Leu Ser Leu Ser Leu Gly Lys
      210             215

```

<210> 30

<211> 281

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1-hyFc8

<400> 30

```

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
  1              5              10             15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Ala
      20              25              30

Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys
      35              40              45

Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu
      50              55              60

Cys Pro Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro Pro Lys
      65              70              75              80

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
      85              90              95

Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr

```

100	105	110
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu		
115	120	125
Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His		
130	135	140
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys		
145	150	155
Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln		
165	170	175
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met		
180	185	190
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro		
195	200	205
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn		
210	215	220
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu		
225	230	235
Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val		
245	250	255
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln		
260	265	270
Lys Ser Leu Ser Leu Ser Leu Gly Lys		
275	280	

<210> 31

<211> 286

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1-hyFc9

<400> 31

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly		
1	5	10
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Ala		
20	25	30
Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly		
35	40	45
Glu Glu Lys Lys Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu		
50	55	60
Thr Lys Thr Pro Glu Cys Pro Ser His Thr Gln Pro Leu Gly Val Phe		
65	70	75
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro		
85	90	95
Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val		
100	105	110
Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr		
115	120	125

Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
 130 135 140
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
 145 150 155 160
 Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser
 165 170 175
 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
 180 185 190
 Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
 195 200 205
 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
 210 215 220
 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
 225 230 235 240
 Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp
 245 250 255
 Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 260 265 270
 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
 275 280 285

<210> 32

<211> 295

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1-hyFc11

<400> 32

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15
 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Ala
 20 25 30
 Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala
 35 40 45
 Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu Lys
 50 55 60
 Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro
 65 70 75 80
 Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro Pro Lys Pro Lys
 85 90 95
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 100 105 110
 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
 115 120 125
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
 130 135 140

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 145 150 155 160
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
 165 170 175
 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 180 185 190
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
 195 200 205
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 210 215 220
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 225 230 235 240
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 245 250 255
 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
 260 265 270
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 275 280 285
 Leu Ser Leu Ser Leu Gly Lys
 290 295

<210> 33

<211> 93

<212> DNA

<213> Homo sapiens

<400> 33

cacgccgaag gcaccttcac cagcgacgtg agcagctacc tggaaggcca ggctgccaag 60
 gagttcatcg cctggctggt gaaaggcaga ggc 93

<210> 34

<211> 93

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-1(7-37) analogue (A8G)

<400> 34

cacggcgaag gcaccttcac cagcgacgtg agcagctacc tggaaggcca ggctgccaag 60
 gagttcatcg cctggctggt gaaaggcaga ggc 93

<210> 35

<211> 90

<212> DNA

<213> Homo sapiens

<400> 35

cacgccgaag gcaccttcac cagcgacgtg agcagctacc tggaaggcca ggctgccaag 60
 gagttcatcg cctggctggt gaaaggcaga 90

<210> 36
 <211> 192
 <212> DNA
 <213> Homo sapiens

<400> 36
 agatggcccg agagccctaa ggcccaggcc agctccgtgc ccacagctca gccacaggct 60
 gaggggaagcc tcgccaaggc aacgactgcg ccggccacta cgcgcaacac cggccgcggc 120
 ggcgaggaga agaagaagga gaaggagaag gaggagcagg aggagcgcga gaccaagacc 180
 cccgagtgcc cc 192

<210> 37
 <211> 105
 <212> DNA
 <213> Homo sapiens

<400> 37
 gcgcgggcca ctacgcgcaa caccggccgc ggcggcgagg agaagaagaa ggagaaggag 60
 aaggaggagc aggaggagcg cgagaccaag acccccagat gcccc 105

<210> 38
 <211> 120
 <212> DNA
 <213> Homo sapiens

<400> 38
 gccaggcaa cgactgcgcc ggccactacg cgcaacaccg gccgcggcgg cgaggagaag 60
 aagaaggaga aggagaagga ggagcaggag gagcgcgaga ccaagacccc cgagtgcgcc 120
 120

<210> 39
 <211> 147
 <212> DNA
 <213> Homo sapiens

<400> 39
 gctcagccac aggtgaggg aagcctcgcc aaggcaacga ctgcgccggc cactacgcgc 60
 aacaccggcc gcggcggcga ggagaagaag aaggagaagg agaaggagga gcaggaggag 120
 cgcgagacca agacccccga gtgcccc 147

<210> 40
 <211> 645
 <212> DNA
 <213> Artificial Sequence

<220>

<223> IgD & IgG4 Hybrid CH2 & CH3 region

<400> 40

```

agccacacccc agcccctggg cgtgttcctg ttcccccca agcccaagga caccctgatg      60
atcagccgca cccccgaggt gacctgctg gtcgtggatg tgagccagga agatcccga      120
gtgcagttca actggtacgt ggatggcgtg gaagtgcaca acgccaagac caagcccaga      180
gaagagcagt tcaactccac ctacagagtg gtgagcgtgc tgaccgtgct gcaccaggac      240
tggctgaacg gcaaggagta caagtgcaag gtgtccaaca aaggcctgcc cagctccatc      300
gagaagacca tcagcaaagc caaaggccag ccagagaaac ccaggtgta caccctgcct      360
cccagccagg aagagatgac caagaaccag gtgtccctga cctgcctggg gaaaggcttc      420
taccacagcg acatgcgcgt ggagtgggaa agcaacggcc agcccgagaa caattacaag      480
acaaccctc cctgctgga tagcgatggc agcttctttc tgtacagcag actgaccgtg      540
gacaagagca gatggcagga aggcaacgtg ttcagctgca gcgtgatgca cgaagccctg      600
cacaaccact acaccagaa gagcctgtcc ctgagcctgg gcaag      645

```

<210> 41

<211> 843

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-1-hyFc8

<400> 41

```

cacggcgaag gcaccttcac cagcgacgtg agcagctacc tggaaggcca ggctgccaag      60
gagttcatcg cctggctggg gaaaggcaga ggcgcgccgg ccactacgcg caacaccggc      120
cgcgcgcgcg aggagaagaa gaaggagaag gagaaggagg agcaggagga gcgcgagacc      180
aagacccccg agtgccccag ccacaccag cccctggcg tgctcctgtt ccccccaag      240
cccaaggaca ccctgatgat cagccgcacc ccgaggtga cctgcgtggg cgtggatgtg      300
agccaggaag atccgaagt gcagttcaac tggtagctgg atggcgtgga agtgcacaac      360
gccaagacca agccagaga agagcagttc aactccacct acagagtggg gagcgtgctg      420
accgtgctgc accaggactg gctgaacggc aaggagtaca agtgcaagg gtccaacaaa      480
ggcctgcca gctccatcga gaagaccatc agcaaagcca aaggccagcc cagagaaccc      540
caggtgtaca ccctgcctcc cagccaggaa gagatgacca agaaccagg gtccctgacc      600
tgcctggtga aaggcttcta ccccgcgac atcgccgtgg agtgggaaag caacggccag      660
cccgagaaca attacaagac aaccctccc gtgctggata gcgatggcag cttctttctg      720
tacagcagac tgaccgtgga caagagcaga tggcaggaa gcaacgtgtt cagctgcagc      780
gtgatgcacg aagccctgca caaccactac acccagaaga gcctgtccct gagcctgggc      840
aag      843

```

<210> 42

<211> 858

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-1-hyFc9

<400> 42

cacggcgaag gcaccttcac cagcgacgtg agcagctacc tggaaggcca ggctgccaaag	60
gagttcatcg cctggctggg gaaaggcaga ggcgccaaag caacgactgc gccggccact	120
acgcgcaaca ccggccgcgg cggcgaggag aagaagaagg agaaggagaa ggaggagcag	180
gaggagcgcg agaccaagac ccccgagtgc ccagccaca ccagcccct gggcgtgttc	240
ctgttcccc ccaagccaa ggacaccctg atgatcagcc gcacccccga ggtgacctgc	300
gtggtcgtgg atgtgagcca ggaagatccc gaagtgcagt tcaactggta cgtggatggc	360
gtggaagtgc acaacgcaa gaccaagccc agagaagagc agttcaactc cacctacaga	420
gtggtgagcg tgctgaccgt gctgcaccag gactggctga acggcaagga gtacaagtgc	480
aaggtgtcca acaaaggcct gccagctcc atcgagaaga ccacagcaa agccaaaggc	540
cagcccagag aaccccaggt gtacaccctg cctcccagcc aggaagagat gaccaagaac	600
caggtgtccc tgacctgcct ggtgaaaggc ttctaccca gcgacatcgc cgtggagtgg	660
gaaagcaacg gccagcccga gaacaattac aagacaacc ctcccgctgt ggatagcgat	720
ggcagcttct ttctgtacag cagactgacc gtggacaaga gcagatggca ggaaggcaac	780
gtgttcagct gcagcgtgat gcacgaagcc ctgcacaacc actacacca gaagagcctg	840
tcctgagcc tgggcaag	858

<210> 43

<211> 885

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-1-hyFc11

<400> 43

cacggcgaag gcaccttcac cagcgacgtg agcagctacc tggaaggcca ggctgccaaag	60
gagttcatcg cctggctggg gaaaggcaga ggcgctcagc cacaggctga ggaagcctc	120
gccaaggcaa cgactgcgc gccactacg cgcaacaccg gccgcggcgg cgaggagaag	180
aagaaggaga aggagaagga ggagcaggag gagcgcgaga ccaagacccc cgagtgcccc	240
agccacaccc agcccctggg cgtgttcctg ttcccccca agcccaagga caccctgatg	300
atcagccgca cccccaggt gacctgcgtg gtcgtggatg tgagccagga agatcccgaa	360
gtgcagttca actggtacgt ggatggcgtg gaagtgcaca acgccaagac caagcccaga	420
gaagagcagt tcaactccac ctacagagtg gtgagcgtgc tgaccgtgct gcaccaggac	480
tggctgaacg gcaaggagta caagtgaag gtgtccaaca aaggcctgcc cagctccatc	540

gagaagacca tcagcaaagc caaaggccag ccagagaaac cccaggtgta caccctgcct 600
 cccagccagg aagagatgac caagaaccag gtgtccctga cctgcctggt gaaaggettc 660
 taccgccgag acatcgccgt ggagtgggaa agcaacggcc agcccgagaa caattacaag 720
 acaacccttc ccgtgctgga tagcgatggc agcttctttc tgtacagcag actgaccgtg 780
 gacaagagca gatggcagga aggcaacgtg ttcagctgca gcgtgatgca cgaagccctg 840
 cacaaccact acaccagaa gagcctgtcc ctgagcctgg gcaag 885

<210> 44
 <211> 33
 <212> PRT
 <213> Homo sapiens

<400> 44
 His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
 1 5 10 15
 Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
 20 25 30

Asp

<210> 45
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-2 analogue (A2G)

<400> 45
 His Gly Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
 1 5 10 15
 Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
 20 25 30

Asp

<210> 46
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-2 analogue (A2V)

<400> 46
 His Val Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
 1 5 10 15
 Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
 20 25 30

Asp

<210> 47

<211> 283

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-2-hyFc8

<400> 47

```

His Gly Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
 1           5           10           15

Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
      20           25           30

Asp Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys
      35           40           45

Lys Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr
      50           55           60

Pro Glu Cys Pro Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro
65           70           75           80

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
      85           90           95

Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn
      100          105          110

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
      115          120          125

Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
      130          135          140

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
145          150          155          160

Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys
      165          170          175

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu
      180          185          190

Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
      195          200          205

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
      210          215          220

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
225          230          235          240

Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly
      245          250          255

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
      260          265          270

Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
      275          280

```

<210> 48

<211> 288

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-2-hyFc9

<400> 48

```

His Gly Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
 1           5           10           15

Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
 20           25           30

Asp Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg
 35           40           45

Gly Gly Glu Glu Lys Lys Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu
 50           55           60

Arg Glu Thr Lys Thr Pro Glu Cys Pro Ser His Thr Gln Pro Leu Gly
 65           70           75           80

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 85           90           95

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro
 100          105          110

Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 115          120          125

Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val
 130          135          140

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 145          150          155          160

Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
 165          170          175

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 180          185          190

Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
 195          200          205

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 210          215          220

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 225          230          235          240

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser
 245          250          255

Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 260          265          270

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
 275          280          285

```

<210> 49

<211> 297

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-2-hyFc11

<400> 49

```

His Gly Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
 1           5           10           15

Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr

                20                25                30

Asp Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala
   35           40           45

Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys
   50           55           60

Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu
 65           70           75           80

Cys Pro Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro Pro Lys
   85           90           95

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 100          105          110

Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr
 115          120          125

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 130          135          140

Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 145          150          155          160

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 165          170          175

Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
 180          185          190

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met
 195          200          205

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 210          215          220

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 225          230          235          240

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 245          250          255

Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val
 260          265          270

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 275          280          285

Lys Ser Leu Ser Leu Ser Leu Gly Lys
 290          295

```

<210> 50

<211> 99

<212> DNA

<213> Homo sapiens

<400> 50
 cacgccgacg gcagcttcag cgacgagatg aacaccatcc tggacaacct ggccgctaga 60
 gacttcatca actggctgat ccagaccaag atcaccgat 99

<210> 51

<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-2 analogue (A2G)

<400> 51
 cacggcgacg gcagcttcag cgacgagatg aacaccatcc tggacaacct ggccgctaga 60
 gacttcatca actggctgat ccagaccaag atcaccgat 99

<210> 52

<211> 849

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-2-hyFc8

<400> 52
 cacggcgacg gcagcttcag cgacgagatg aacaccatcc tggacaacct ggccgctaga 60
 gacttcatca actggctgat ccagaccaag atcaccgatg cgccggccac tacgcgcaac 120
 accggccgcg gcgccgagga gaagaagaag gagaaggaga aggaggagca ggaggagcgc 180
 gagaccaaga ccccgagtg ccccgaccac acccagcccc tgggcgtgtt cctgttcccc 240
 cccaagcca aggacacct gatgatcagc cgcacccccg aggtgacctg cgtggtcgtg 300
 gatgtgagcc aggaagatcc cgaagtgcag ttcaactggt acgtggatgg cgtggaagtg 360
 cacaacgcca agaccaagcc cagagaagag cagttcaact ccacctacag agtggtgagc 420
 gtgctgaccg tgctgcacca ggactggctg aacggcaagg agtacaagtg caagggtgtcc 480
 aacaaaggcc tgcccagctc catcgagaag accatcagca aagccaaagg ccagcccaga 540
 gaaccccagg tgtacacctt gcctcccagc caggaaagaga tgaccaagaa ccagggtgtcc 600
 ctgacctgcc tggtgaaagg cttctacccc agcgacatcg ccgtggagtg ggaaagcaac 660
 ggccagcccg agaacaatta caagacaacc cctcccgtgc tggatagcga tggcagcttc 720
 tttctgtaca gcagactgac cgtggacaag agcagatggc aggaaggcaa cgtgttcagc 780
 tgcagcgtga tgcacgaagc cctgcacaac cactacaccc agaagagcct gtccttgagc 840
 ctgggcaag 849

<210> 53

<211> 864

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-2-hyFc9

<400> 53

cacggcgacg gcagcttcag cgacgagatg aacaccatcc tggacaacct ggccgctaga	60
gacttcatca actggctgat ccagaccaag atcaccgatg ccaaggcaac gactgcgccg	120
gccactacgc gcaacaccgg ccgcgggcggc gaggagaaga agaaggagaa ggagaaggag	180
gagcaggagg agcgcgagac caagaccccc gagtgcccca gccacacca gccctgggc	240
gtgttcctgt tccccccaa gccaaggac accctgatga tcagccgcac ccccgaggtg	300
acctgcgtgg tcgtggatgt gagccaggaa gatcccgaa tgcagttcaa ctggtacgtg	360
gatggcgtgg aagtgcacaa cgccaagacc aagcccagag aagagcagtt caactccacc	420
tacagagtgg tgagcgtgct gaccgtgctg caccaggact ggctgaacgg caaggagtac	480
aagtgaagg tgtccaacaa aggcctgccc agctccatcg agaagaccat cagcaaagcc	540
aaaggccagc ccagagaacc ccagggtgtac accctgcctc ccagccagga agagatgacc	600
aagaaccagg tgtccctgac ctgcctgggtg aaaggcttct accccagcga catcgccgtg	660
gagtgggaaa gcaacggcca gcccgagaac aattacaaga caaccctcc cgtgctggat	720
agcgatggca gcttctttct gtacagcaga ctgaccgtgg acaagagcag atggcaggaa	780
ggcaacgtgt tcagctgcag cgtgatgcac gaagccctgc acaaccacta caccagaag	840
agcctgtccc tgagcctggg caag	864

<210> 54

<211> 891

<212> DNA

<213> Artificial Sequence

<220>

<223> GLP-2-hyFc11

<400> 54

cacggcgacg gcagcttcag cgacgagatg aacaccatcc tggacaacct ggccgctaga	60
gacttcatca actggctgat ccagaccaag atcaccgatg ctccagccaca ggctgaggga	120
agcctcgcca aggcaacgac tgcgcgggcc actacgcgca acaccggccg cggcggcgag	180
gagaagaaga aggagaagga gaaggaggag caggaggagc gcgagaccaa gacccccgag	240
tgccccagcc acaccagcc cctgggcgtg ttcctgttcc cccccaagcc caaggacacc	300
ctgatgatca gccgcacccc cgagggtgacc tgcgtggtcg tggatgtgag ccaggaagat	360
cccgaagtgc agttcaactg gtacgtggat ggcgtggaag tgcacaacgc caagaccaag	420
cccagagaag agcagttcaa ctccacctac agagtggatga gcgtgctgac cgtgctgcac	480
caggactggc tgaacggcaa ggagtacaag tgcaagggtg ccaacaaagg cctgcccagc	540
tccatcgaga agaccatcag caaagccaaa ggccagccca gagaaccca ggtgtacacc	600

ctgcctccca gccaggaaga gatgaccaag aaccaggtgt ccctgacctg cctggtgaaa	660
ggcttctacc ccagcgacat cgccgtggag tgggaaagca acggccagcc cgagaacaat	720
tacaagacaa cccctcccgt gctggatagc gatggcagct tctttctgta cagcagactg	780
accgtggaca agagcagatg gcaggaaggc aacgtgttca gctgcagcgt gatgcacgaa	840
gccctgcaca accactacac ccagaagagc ctgtccctga gcctgggcaa g	891

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US7452966B2](#) [0007] [0029] [0051] [0110]
- [WO2008147143A](#) [0017] [0039] [0081] [0085]
- [US20070117752A1](#) [0036]
- [WO0016797A](#) [0061]
- [WO9808531A](#) [0061]
- [WO9819698A](#) [0061]
- [US6006753A](#) [0061]
- [WO9964060A](#) [0061]
- [WO0007617A](#) [0061]
- [KR1020140195793](#) [0120]

Patentkrav

1. Et fusionspolypeptid, der omfatter (a) glukagon-lignende peptid (GLP) eller en analog deraf, og (b) et immunoglobulin Fc-polypeptid, hvori immunoglobulin Fc-polypeptidet omfatter (i) en isoleret IgD-hængselregion, der består af en aminosyresekvens på 35 til 49 efterfølgende aminosyrerester fra C-terminalen for SEQ ID NO: 25; og (ii) et CH2-domæne og et CH3-domæne for immunoglobulin Fc-polypeptidet.
2. Fusionspolypeptidet i krav 1, hvori GLP er GLP-1, og fortrinsvis hvori GLP-1 består af en aminosyresekvens for SEQ ID NO: 1 eller SEQ ID NO: 13.
3. Fusionspolypeptidet i krav 2, hvori analogen af GLP-1 omfatter en modifikation på et sted, der kan kløves af DPP-4-enzym, og består af en aminosyresekvens, der er valgt ud fra gruppen, der består af SEQ ID NO: 2 til 12 og SEQ ID NO: 14 til 24.
4. Fusionspolypeptidet i krav 1, hvori GLP er GLP-2, og fortrinsvis, hvori GLP-2 består af en aminosyresekvens for SEQ ID NO: 44.
5. Fusionspolypeptidet i krav 4, hvori en analog af GLP-2 omfatter en modifikation på et sted, der kan kløves af DPP-4-enzym, og består af en aminosyresekvens med SEQ ID NO: 45 eller SEQ ID NO: 46.
6. Fusionspolypeptidet i krav 1, hvori IgD-hængselsområdet består af en aminosyresekvens, der er valgt ud fra den gruppe, der består af SEQ ID NO: 26 til 28.
7. Fusionspolypeptidet i krav 1, hvori fusionspolypeptidet udviser en øget halveringstid til sammenligning med polypeptidet, der ikke er fusioneret med immunoglobulin Fc-polypeptidet.

8. Fusionspolypeptidet i krav 1, hvori fusionspolypeptidet består af en aminosyresekvens, der er valgt ud fra den gruppe, der består af SEQ ID NO: 30 til 32 og SEQ ID NO: 47 til 49.

5 **9.** En farmakologisk sammensætning til brug ved behandling af diabetes, som omfatter fusionspolypeptidet i krav 2 som en aktiv ingrediens.

10 **10.** En farmakologisk sammensætning til brug ved behandling af inflammatorisk tarmsygdom, tarmslimhindeinflammation eller diarré, som er forårsaget af kræftbehandling med kemoterapi, eller korttarmssyndrom, som omfatter fusionspolypeptidet i krav 4 som en aktiv ingrediens.

15 **11.** En polynukleotid, der koder fusionspolypeptidet i henhold til ethvert af krav 1 til 8.


20 **12.** Polypeptidet i krav 11, hvori polypeptidet består af en nukleinsyresekvens, der er valgt ud fra den gruppe, der består af SEQ ID NO: 41 til 43 og SEQ ID NO: 52 til 54.

25 **13.** En expressionsvektor, der omfatter polynukleotidet i krav 11.

30 **14.** En værtselle, der omfatter expressionsvektoren i krav 13.

DRAWINGS


[FIG. 1]




GLP-1-hyFc5

HGEFTFTSDVSSYLEGQAAKEFIAWLVGRGRNTGRGGE
EKKKEKEKEEQEERETKTPECPSHTQPLGVFLFPPKPKD
 TLMISRTPEVTCVVVDVSOEDPEVQENWYVDGVEVHNAK
 TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG
 LPSSIETISKAKGQPREPQVYTLPPSQEEMTKNOVSLT
 CLVKGFPYPSDIAVEWESNGOPENNYKTPPVLDSDGSFF
 LYSRLTVDKSRWQEGNVFSCSVMHREALHNHYTQKSLSLS
 LGK


[FIG. 2]




[FIG. 3]




[FIG. 4]




[FIG. 5]




[FIG. 6]




[FIG. 7]




[FIG. 8]




[FIG. 9]




[FIG. 10]




[FIG. 11]



[FIG. 12]




[FIG. 13]




[FIG. 14]


Proliferation of CaCo-2 cells treated with drug-conditioned media of CCD-18co cells (Indirect effect)




[FIG. 15]



[FIG. 16]



[FIG. 17]



- 5-FU control group showed 27 % morbidity
- GLP-2-hyFc9 group showed 6.7 % morbidity

On day 13 (End point of the monitoring)	Survival/Total (no. of rats)
Negative control	15/15
5-FU 75 mg/kg	11/15
G4(5-FU+GX-G8 80 nmol/kg)	14/15